Business Context and Reporting Period
This Form 6-K filing by Scinai Immunotherapeutics Ltd. reports on the Annual Meeting of Shareholders held on December 22, 2025. The filing covers corporate governance actions, including director elections, amendments to the Articles of Association, and equity compensation approvals. The reporting period is December 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on shareholder voting results and corporate actions rather than financial performance data.
Material Changes and Corporate Actions
- Shareholder Participation: Of 13,872,899,584 ordinary shares entitled to vote, 2,498,440,000 shares were present, constituting a quorum.
- Board Composition: Mr. Mark Germain was re-elected as a director. Prof. Avner Rotman and Dr. Morris Laster voluntarily stepped down from the Board as part of cost-cutting measures.
- Capital Structure: Shareholders approved an amendment to the Articles of Association to increase the number of authorized Ordinary Shares.
- Equity Compensation:
- 60,000 restricted share units granted to CEO Amir Reichman.
- Options to purchase ADSs granted to five continuing directors.
- Options granted and vesting accelerated for the two departing directors (Prof. Rotman and Dr. Laster).
- ADSs granted to Dr. Tamar Ben-Yedidia for service as an officer.
- Auditor Appointment: Zvi Haft (BDO) was ratified as the auditor for 2025 and the subsequent period.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, or specific risk factors. Management commentary is limited to the rationale for equity grants, citing performance recognition and cost-cutting measures associated with the departure of two directors.
Investor Verification Checklist
- Verify the impact of the increased authorized share count on potential future dilution.
- Confirm the specific terms and vesting schedules of the new equity grants to the CEO and directors.
- Review the company's most recent financial statements (Form 20-F) for actual liquidity and cash burn rates, as this filing contains no financial data.
- Assess the effectiveness of the cost-cutting measures initiated by the reduction of the Board size.